StockNews.AI
CLSD
StockNews.AI
90 days

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

1. Clearside to participate in Stifel's Virtual Ophthalmology Forum on May 27, 2025. 2. Management will discuss innovations in therapies for eye diseases. 3. The company's lead program, CLS-AX, is advancing towards Phase 3 trials. 4. SCS Microinjector allows targeted delivery of therapies for eye conditions. 5. Clearside's first product, XIPERE®, is commercially available in the U.S.

4m saved
Insight
Article

FAQ

Why Bullish?

The participation in a prominent forum could enhance visibility and credibility, contributing to potential investor confidence, historically correlating with price increases in similar biotech forums. For example, companies like Regeneron saw stock upticks after significant announcements in conferences.

How important is it?

The article emphasizes proactive steps by Clearside, indicating growth potential and increasing investor interest.

Why Short Term?

The upcoming forum creates immediate buzz, likely affecting stock price shortly after the event. Previous events have led to price adjustments within weeks of similar presentations.

Related Companies

REGNRGENSPPI
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X. Source: Clearside Biomedical, Inc.

Related News